Endarterectomy Versus Stenting in Patients With Symptomatic Severe Carotid Stenosis - 2
ConditionStroke
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Hospitalier St Anne
About this trial
Carotid stenosis caused by atherosclerosis is a significant risk factor for ischemic stroke, accounting for up to 15% of all strokes and transient ischemic attacks. Randomized clinical trials (RCTs) have demonstrated the benefits of carotid endarterectomy (CEA) in reducing stroke risk in patients with severe symptomatic carotid stenosis. Carotid artery stenting (CAS) has been developed as an alternative to CEA, offering several potential advantages, such as avoiding local surgical complications. However, unlike CEA, CAS has not been compared to medical therapy in RCTs for symptomatic carotid stenosis.
Eligibility criteria
Qualifiers
Patient age 18 years or over
Hemispheric or retinal transient ischemic attack or a non-disabling stroke (or retinal infarct) within 15 days before enrolment
Stenosis of 50% to 99% in the symptomatic carotid artery (NASCET method) for whom revascularisation is decided according to guidelines
Disqualifiers
Patients unwilling or unable to participate in follow-up for whatever reason
Preexisting disability (Modified Rankin Score ≥ 3)
Nonatherosclerotic carotid disease
Severe tandem lesions
Trial design
Treatments tested in this trial
- carotid endarterectomy
- Carotid artery stenting
Treatment groups
600 Participants
are divided into 2 treatment groupsSponsors and collaborators
Centre Hospitalier St Anne
Lead sponsor
Direction Générale de l'Offre de Soins
Collaborator
Source ClinicalTrials.gov